To address variation of TIGIT+KLRG1+ CD8 T cells in the absence of therapy, we first investigated the stability of these cells in vivo in a T1D cohort (Table 1, Supplementary Figure 1) measuring the proportion of TIGIT+KLRG1+ CD8+ T cells at multiple time points over two years (Figure 1A). This evidence concerns the gene CD8A and type 1 diabetes mellitus.